Nanobiotix has presented promising preclinical data on its Nanoprimer platform, which aims to enhance the efficacy of lipid nanoparticle (LNP)-delivered therapies by addressing rapid liver clearance issues. In a mouse model, pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (LNP-DNA) for anti-tumor immunotherapy resulted in increased systemic bioavailability, reduced hepatic toxicity, and mitigated cGAS-STING related inflammation compared to LNP-DNA alone. This study was showcased at the 2026 Annual Meeting of the American Association for Cancer Research.

The significance of these findings lies in their potential to overcome a major limitation of LNP-DNA therapies: the swift clearance by the mononuclear phagocyte system (MPS), which hampers therapeutic delivery to tumors and heightens liver toxicity. The data indicate that Nanoprimer effectively transiently occupies hepatic clearance pathways, leading to decreased liver uptake of LNP-DNA and improved tolerability. Furthermore, the attenuation of inflammatory responses associated with the cGAS-STING pathway suggests that Nanoprimer could enhance the safety profile of LNP-based therapies, making them more viable for clinical applications.

The implications for the field are substantial, as this approach could shift the paradigm of LNP delivery systems. By integrating Nanoprimer with advanced LNP formulations, researchers may unlock new therapeutic avenues for complex treatments, including RNA and gene therapies, that have previously been limited by hepatic accumulation. This advancement not only enhances the performance of existing therapies but also paves the way for the development of novel therapeutic strategies that maximize efficacy while minimizing toxicity.

Source: globenewswire.com